Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average rating of “Moderate Buy” from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $117.00.

MIRM has been the subject of a number of recent analyst reports. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Royal Bank Of Canada reduced their target price on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Stifel Nicolaus raised their price target on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Morgan Stanley lifted their price target on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Finally, Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th.

Insider Buying and Selling

In other news, SVP Jolanda Howe sold 968 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $99,994.40. Following the sale, the senior vice president owned 4,503 shares in the company, valued at approximately $465,159.90. This represents a 17.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 1,053 shares of the stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $101,288.07. Following the transaction, the chief financial officer directly owned 43,741 shares in the company, valued at $4,207,446.79. The trade was a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 45,136 shares of company stock worth $4,352,029. 22.87% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Cullen Frost Bankers Inc. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $30,000. MCF Advisors LLC raised its position in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in Mirum Pharmaceuticals during the fourth quarter worth $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals during the fourth quarter worth $32,000. Finally, Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the third quarter worth $33,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $88.78 on Tuesday. The firm has a 50-day moving average of $94.42 and a two-hundred day moving average of $80.22. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The stock has a market cap of $5.36 billion, a P/E ratio of -184.95 and a beta of 0.52. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The business had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same period in the previous year, the firm posted $1.00 earnings per share. The firm’s revenue was up 49.8% compared to the same quarter last year. On average, research analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.